|
|||||
|
|
Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer: An International Collaborative Cancer Group (ICCG) study |
|
| Authors: | Coombes, R. C. Chilvers, C. E. D. Amadori, D. Medi, F Fountzilas, G. Rauschecker, H. Vassilopoulos, P. Ferreira, E. Pinto Vannozzi, G. Bliss, J. M. Woods, E. Wils, J. |
| Affiliation: | 1Medical Oncology Unit, Charing Cross Hospital London 2Institute of Cancer Research Sutton, Surrey, UK 3Ospedale GB Morgagni-L Pierantoni, Forli 4Istituto Patologia Chirurgica Pisa, Italy 5Ahepa University Hospital Thessaloniki, Greece 6Chirurgische Universitats-Klinik Gottingen, Germany 7Saint Savvas Anti-Cancer Institute Athens, Greece 8Instituto Portugues de Oncologia Oporto, Portugal 9Unita Operativa di Gastroenterologia USL 10D Florence, Italy 10St. Laurentius Ziekenhuis Roermond, The Netherlands |
| Abstract: | Background: It is not yet established whether doses of epirubicinequitoxic to adriamycin are more effective in the treatmentof locally advanced or metastatic gastric cancer. Patients and methods: Seventy patients with advanced gastriccancer were randomised to receive fluorouracil (500 mg/m2 days15 every three weeks) or epirubicin (100 mg/ m2 everythree weeks), with doses escalating to a maximum dose of 700mg/m2 of fluorouracil or 140 mg/m2 of epirubic Results: No patients attained complete response. Partial responsewas seen in 3 patients in the epirubicin arm (8%) compared with2 patients in the fluorouracil arm (6%). No statistically significantdifference between the two treatments was seen in either responseor survival. Severe side effects, particularly alopecia, andnausea and vomiting were more common in the epirubicin arm (45%and 37%, respectively) compared with the fluorouracil arm (12%and 8%, respectively). Conclusions: Our trial demonstrates that fluorouracil and epirubicinas single agents have comparable but insufficient activity inadvanced gastric cancer. stomach cancer, chemotherapy, anthracycline |
| Keywords: | |
| 本文献已被 Oxford 等数据库收录！ | |